Dechra adds Clavubactin® to antibiotic portfolio

Dechra adds Clavubactin® to antibiotic portfolio

22 July 2019

A new addition to the antibiotic range that targets a wide range of bacterial infections in cats and dogs has been unveiled by Dechra Veterinary Products.

Clavubactin®, which combines active ingredients amoxicillin and clavulanic acid, is indicated to treat urinary tract, respiratory, gastrointestinal, oral and skin infections.

It is highly effective against common bacteria including Staphylococci, Clostridia, Corynebacteria and Streptococci, and gram-negative bacteria including Bacteroides spp, Pasteurellae, and Proteus spp.

Clavubactin, which is available in a range of dose strengths to treat all sizes of patient, has been produced to encourage the effective and responsible use of antibiotics.

Its easy double divisibility ensures accurate and flexible dosing to help avoid development of antibiotic resistance associated with under dosing. The blister packs are quick and easy to dispense in packs of 10 tablets and reduce unnecessary exposure when dispensing in practice.

Dechra Brand Manager Carol Morgan said: “The introduction of Clavubactin to our antibiotic portfolio will give veterinary professionals even more choice of effective and targeted treatments in their day-to-day practice.”

Dechra’s antibiotic range already includes Spizobactin®, Doxybactin®, Cefabactin® and Metrobactin®.

For more information visit